NCT01423539View on ClinicalTrials.gov

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

bendamustine

Intravenous repeating dose\\n

DRUG

navitoclax

Oral repeating dose\\n

DRUG

rituximab

Intravenous repeating dose\\n

Trial Locations (13)

20850

Rockville

30045

Lawrenceville

34667

Hudson

37203

Nashville

41701

Hazard

42003

Paducah

43055

Newark

47802

Terre Haute

59405

Great Falls

60426

Harvey

62801

Centralia

65109

Jefferson City

92708

Fountain Valley

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

collaborator

AbbVie (prior sponsor, Abbott)

INDUSTRY

lead

Genentech, Inc.

INDUSTRY

NCT01423539 - A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) | Biotech Hunter | Biotech Hunter